American Regent vs. Cipla: Selenious Acid Patent Litigation Consolidated
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. Cipla Limited |
| Case Number | 2:24-cv-11112 (consolidated into 2:24-cv-7791) |
| Court | District of New Jersey |
| Duration | Dec 2024 – Jan 2025 21 days |
| Outcome | Case Consolidated |
| Patents at Issue | |
| Accused Products | Cipla’s selenious acid pharmaceutical preparations |
Case Overview
The Parties
⚖️ Plaintiff
U.S.-based specialty pharmaceutical company with a focused portfolio in injectable products, including parenteral nutrition components.
🛡️ Defendant
Multinational generic pharmaceutical manufacturer with a significant U.S. market presence through its subsidiary Cipla USA, Inc.
Patents at Issue
This case centers on U.S. Patent No. US12150957B2, covering selenious acid products — a critical component in intravenous trace element formulations used in clinical nutrition.
- • US12150957B2 — Selenious acid pharmaceutical formulations (Application No. US18/672876)
Developing a similar pharmaceutical product?
Check if your selenious acid formulation might infringe this or related patents.
The Verdict & Legal Analysis
Outcome: Consolidation, Not Dismissal
The closure of Case No. 2:24-cv-11112 on January 3, 2025, represents a procedural consolidation, not a substantive verdict. All claims against Cipla Limited and Cipla USA, Inc. have been transferred into the consolidated **In re Selenious Acid Litigation** master docket (Civil Action No. 2:24-cv-7791). No damages were awarded, no injunction was issued, and no merits determination was made in this individual action. The litigation against Cipla continues under the consolidated caption.
Key Legal Issues
The stipulated consolidation order reflects a classic Hatch-Waxman litigation architecture. When a branded pharmaceutical manufacturer faces multiple generic challengers filing substantially similar ANDA applications referencing the same reference listed drug, simultaneous filing followed by consolidation achieves several critical litigation objectives.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis: Selenious Acid
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View related ANDA filings and competitive landscape
- See which companies are most active in selenious acid patents
- Understand claim construction patterns relevant to formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your pharmaceutical formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Selenious acid intravenous formulations
1 Patent at Issue
US12150957B2 in this case
ANDA Litigation
Consolidated multi-defendant action
✅ Key Takeaways
For Patent Attorneys
Simultaneous multi-defendant filing followed by immediate consolidation is a powerful Hatch-Waxman enforcement architecture.
Search related case law →New Jersey District Court remains a premier venue for pharmaceutical patent consolidation and ANDA-related disputes.
Explore precedents →For R&D Teams
Conduct updated FTO analysis against US12150957B2 before advancing any selenious acid intravenous formulation program.
Start FTO analysis for my product →Monitor consolidated claim construction rulings for scope determinations affecting design-around viability for generic products.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.